| Description |
1 online resource |
| Physical Medium |
polychrome |
| Description |
text file |
| Bibliography |
Includes bibliographical references and index. |
| Contents |
PREFACE ; List of Contributors ; Melatoninergic Pathways in Alzheimer's Disease ; 1. INTRODUCTION; 2. ALZHEIMER'S DISEASE OVERVIEW; 2.1. Classical Alzheimer's Disease Pathophysiology; 2.2. Systemic Immune Inflammation and AD; 2.3. Oxidative and Nitrosative Stress, Cytokines and Tryptophan Catabolites; 2.4. Oxidative and Nitrosative Stress and Cellular Damage; 2.5. ApoE4; 2.6. Immuno-Senescence and Alzheimer's Disease; 2.7. Circadian Rhythms and Alzheimer's Disease; 2.8. Conclusions on Alzheimer's Disease Processes; 3. MELATONINERGIC PATHWAYS OVERVIEW; 3.1. Immune-Pineal Axis. |
|
2.1.3. Acetylcholinesterase Inhibitors2.1.4. Tyrosine Kinase Inhibitors; 2.1.5. Omega-3 Polyunsaturated Fatty Acids; 2.1.6. Curcumin; 2.1.7. Co-Enzyme Q10; 2.1.8. Green Tea; 2.1.9. Coffee and Caffeine; 2.1.10. Ferulic Acid; 2.1.11. B-vitamins and Folate; 2.1.12. Cigarette Smoking; 2.1.13. Cotinine; 2.1.14.-α7nAChr Agonists; 2.1.15. Zinc; 2.1.16. Taurine; 3. POSSIBLE INTEGRATING MODEL; 4. FUTURE DIRECTIONS; 4.1. Astrocyte Mitochondria; 4.2. Estrogen Receptors; 4.3. Thiazolidinediones/PPAR-γ Agonists; 4.4. Retinoid X Receptor Agonists; 4.5. MAOIs; 4.6. MeCP2 and Epigenetics. |
|
4. ALZHEIMER'S DISEASE: MELATONIN AND NAS4.1. Melatonin and AD; 4.2. Melatonin and AD Models; 4.3. Melatonin in AD Treatment ; 4.4. Alzheimer's Disease: Local Melatonin And NAS ; 4.5. Other Potential Local Melatonin Regulators; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Pharmaceutical and Nutritional Benefits in Alzheimer's Disease via Convergence on the Melatoninergic Pathways ; 1. INTRODUCTION; 1.1. Methods; 2. PHARMACOLOGICAL AND DIETARY TREATMENTS; 2.1. Overview; 2.1.1. Serotonin, Tryptophan and SSRIs; 2.1.2. Monoamine Oxidase Inhibitors. |
|
CONFLICTS OF INTERESTACKNOWLEDGEMENTS; REFERENCES; Some Questions Posed About the Prevention and Treatment of Alzheimer's Disease ; INTRODUCTION; 1. WHAT IS THE NEED FOR PREVENTION AND TREATMENT OF AD?; 2. DOES IT MAKE SENSE TO SEPARATE PREVENTION AND TREATMENT OF AD?; 3. DO WE KNOW ENOUGH ABOUT THE AETIOLOGY AND PATHOGENESIS OF AD TO BE ABLE TO PREVENT OR TREAT IT?; 4. SHOULD A-BETA42 BE THE MAIN THERAPEUTIC TARGET FOR TREATMENT STRATEGIES IN AD?; 5. WHY IS DIAGNOSIS IMPORTANT IN PREVENTING AND TREATING AD? |
|
4.7. NE and Beta-Adrenergic Receptors4.8. Depression and Autoimmunity; 4.9. Obesity and AD risk; 4.10. Allergies, Immunoglobulin-E and Mast Cells; 4.11. MicroRNAs; 4.12. Nicotinamide (NAD)+ ; 4.13. Astrocyte Networks; 4.14. ApoE4: Astrocyte Versus Neuronal; 4.15. Melatonin and Immuno-senescence; 4.16. S1P; 4.17. 14-3-3 Isoform Regulation; 4.18. α7nAChr, Cotinine, MAO and Melatonin; 4.19. Ketamine; 4.20. Gut Permeability; 4.21. Homocysteine; 4.22. Valproate and Taurine; 4.23. Walnut; 4.24. Selenium; 4.25. Iron and Transferrin; 4.26. New Pharmaceutical and Dietary Targets; CONCLUSION. |
| Local Note |
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - North America |
| Subject |
Alzheimer's disease -- Treatment.
|
|
Alzheimer's disease -- Treatment. |
|
Alzheimer's disease. |
|
Senile dementia -- Treatment.
|
|
Senile dementia -- Treatment. |
|
Senile dementia. |
|
Pharmacology.
|
|
Pharmacology. |
|
Drugs -- Design.
|
|
Drugs -- Design. |
| Genre/Form |
Electronic books.
|
| Subject |
Medication. |
| Added Author |
Rahman, Atta-ur-, 1942- editor.
|
| Other Form: |
Print version: Atta-ur-Rahman. Frontiers in Clinical Drug Research - Alzheimer Disorders. Sharjah : Bentham Science Publishers, ©2015 9781681081489 |
| ISBN |
1681081474 (electronic book) |
|
9781681081472 (electronic book) |
|
